

CSC-Tübingen PhD Scholarship Program

2025 application round prospective PhD positions at the University of Tübingen

Faculty: Medical Faculty

Institute / Section / Subject: Institute for Medical Virology, Section Molecular Virology

Supervising Professor(s): Prof. Dr. Michael Schindler

About the Supervisor(s): The research involves identification and characterization of viral

immune evasion mechanisms and how these can be manipulated or subverted for innovative therapeutic approaches. We use cutting-edge and state-of-the art methodology, i.e. live cell super-resolution imaging, high-throughput screening, innovative proteomics and flow-cytometry

analyses, single cell techniques etc.

Visit our labpage



Meet us on X



https://orcid.org/0000-0001-8989-5813

https://www.webofscience.com/wos/author/record/C-1647-2015 https://www.scopus.com/authid/detail.uri?authorld=35337858900

Specification: Immune-evasion mechanisms of emerging RNA viruses.

Topic Description: Ebola virus and SARS-CoV-2 are both emerging RNA-viruses and the

cause for fatal disease in humans. The goal of this project will be to decipher how both viruses, as emerging RNA viruses, escape the antiviral immune response. The focus will be on viral manipulation of the plasma membrane and formation of virosomes by these viruses (Nehls et al., CellRep, 2019, PMID: 30759394). By this, we will identify and follow up on novel targets for antiviral therapy or therapeutic and

prophylactic vaccination.

Intended Degree: PhD in Experimental Medicine or Dr. rer. nat. Participation in structured

doctoral program, the IGIM or the PhD Program in Experimental

Medicine.

Type of the PhD Study: Full time complete doctoral studies at the University of Tübingen

Required Degrees: MSc in biomedical sciences, biochemistry, biotechnology, biology,

molecular medicine or related areas.

Language Requirements: English, fluently, written and spoken

Notes: This work does involve research in a biosafety level (BSL)-3 laboratory,

however <u>no</u> handling of replication-competent Ebola virus in a BSL-4

setting.